WST Stock Analysis: West Pharmaceutical | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 29.323m USD | 12M Return: 48.6% | US9553061055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 212M
EPS Trend: 46.1%
Qual. Beats: 7
Rev. Trend: 85.4%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
West Pharmaceutical Services, Inc. (NYSE: WST) is a global manufacturer of containment and delivery systems for injectable drugs and healthcare products, operating across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1923 and headquartered in Exton, Pennsylvania, the company runs two segments: Proprietary Products, which includes stoppers, seals, syringe and cartridge components, drug reconstitution and transfer technologies, self-injection devices, and packaging-related services for biologic, generic, and pharmaceutical drug companies; and Contract-Manufactured Products, which provides design, manufacturing, and automated assembly of devices for surgical, diagnostic, ophthalmic, and other drug delivery applications. Products are sold through a direct sales force, distribution network, contract sales agents, and regional distributors.
The company sits within the Health Care Supplies sub-industry, supplying critical primary packaging components (such as elastomer stoppers and seals) that are integral to injectable drug safety and sterility, often embedded in long-term supply agreements with pharmaceutical manufacturers. As a large-cap player in its segment, WSTs business model is anchored to the growth of biologics and complex injectable therapies, where high regulatory and quality barriers limit competition and support pricing power.
- GLP-1 and biologic injectable drug demand lifts Proprietary Products revenue
- Contract-Manufactured segment pressured by customer inventory destocking
- High-value product mix shift supports operating margin expansion
| Net Income: 638.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.93 > 1.0 |
| NWC/Revenue: 34.51% < 20% (prev 39.37%; Δ -4.86% < -1%) |
| CFO/TA 0.16 > 3% & CFO 654.5m > Net Income 638.9m |
| Net Debt (-57.0m) to EBITDA (966.9m): -0.06 < 3 |
| Current Ratio: 2.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.8m) vs 12m ago -2.61% < -2% |
| Gross Margin: 37.59% > 18% (prev 35.59%; Δ 2.00% > 0.5%) |
| Asset Turnover: 83.19% > 50% (prev 73.49%; Δ 9.70% > 0%) |
| Interest Coverage Ratio: 57.59 > 6 (EBIT TTM 783.2m / Interest Expense TTM 13.6m) |
| A: 0.29 (Total Current Assets 1.82b - Total Current Liabilities 644.3m) / Total Assets 4.06b |
| B: 1.19 (Retained Earnings 4.82b / Total Assets 4.06b) |
| C: 0.19 (EBIT TTM 783.2m / Avg Total Assets 4.08b) |
| D: 2.72 (Book Value of Equity 2.97b / Total Liabilities 1.09b) |
| Altman-Z'' = 9.90 = AAA |
| DSRI: 1.06 (Receivables 748.2m/625.0m, Revenue 3.40b/3.02b) |
| GMI: 0.95 (GM 35.59% / 37.59%) |
| AQI: 1.08 (AQ_t 0.12 / AQ_t-1 0.11) |
| SGI: 1.13 (Revenue 3.40b / 3.02b) |
| TATA: -0.00 (NI 638.9m - CFO 654.5m) / TA 4.06b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of November 02, 2026, the stock is trading at USD 412.62 with a total of 1,062,303 shares traded. Over the past week, the price has changed by +5.22%, over one month by +9.56%, over three months by +21.51% and over the past year by +48.60%.
Current recommended Stop Loss: 401.60 (which is 2.7% or 1.1 ATR below the current price).
West Pharmaceutical has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy WST.
- StrongBuy: 12
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 416.4 | 0.9% |
P/E Trailing = 53.3508
P/E Forward = 41.4938
P/S = 8.8143
P/B = 9.4999
P/EG = 3.1427
Revenue TTM = 3.40b USD
EBIT TTM = 783.2m USD
EBITDA TTM = 966.9m USD
Long Term Debt = 202.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.5m USD (from shortTermDebt, last quarter)
Debt = 407.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 102.1m
Net Debt = -57.0m USD (calculated: Debt 407.1m - CCE 464.1m)
Enterprise Value = 29.3b USD (29.3b + Debt 407.1m - CCE 464.1m)
Interest Coverage Ratio = 57.59 (Ebit TTM 783.2m / Interest Expense TTM 13.6m)
EV/FCF = 64.55x (Enterprise Value 29.3b / FCF TTM 453.4m)
FCF Yield = 1.55% (FCF TTM 453.4m / Enterprise Value 29.3b)
FCF Margin = 13.35% (FCF TTM 453.4m / Revenue TTM 3.40b)
Net Margin = 18.81% (Net Income TTM 638.9m / Revenue TTM 3.40b)
Gross Margin = 37.59% ((Revenue TTM 3.40b - Cost of Revenue TTM 2.12b) / Revenue TTM)
Gross Margin QoQ = 39.73% (prev 37.74%)
Tobins Q-Ratio = 7.21 (Enterprise Value 29.3b / Total Assets 4.06b)
Interest Expense / Debt = 3.34% (Interest Expense 13.6m / Debt 407.1m)
Taxrate = 21.20% (168.2m / 793.3m)
NOPAT = 617.1m (EBIT 783.2m * (1 - 21.20%))
Current Ratio = 2.82 (Total Current Assets 1.82b / Total Current Liabilities 644.3m)
Debt / Equity = 0.14 (Debt 407.1m / totalStockholderEquity, last quarter 2.97b)
Debt / EBITDA = -0.06 (Net Debt -57.0m / EBITDA 966.9m)
Debt / FCF = -0.13 (Net Debt -57.0m / FCF TTM 453.4m)
Total Stockholder Equity = 3.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.65% (Net Income 638.9m / Total Assets 4.06b)
RoE = 21.08% (Net Income TTM 638.9m / Total Stockholder Equity 3.03b)
RoCE = 24.22% (EBIT 783.2m / Capital Employed (Equity 3.03b + L.T.Debt 202.9m))
RoIC = 18.90% (NOPAT 617.1m / Invested Capital 3.27b)
WACC = 6.44% (E(29.3b)/V(29.7b) * Re(6.49%) + D(407.1m)/V(29.7b) * Rd(3.34%) * (1-Tc(0.21)))
Discount Rate = 6.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.71 | Cagr: -1.77%
[DCF] Terminal Value 77.97% ; FCFF base≈423.7m ; Y1≈485.7m ; Y5≈714.8m
[DCF] Fair Price = 153.7 (EV 10.8b - Net Debt -57.0m = Equity 10.8b / Shares 70.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 46.08 | EPS CAGR: 5.41% | SUE: 4.0 | # QB: 7
Revenue Correlation: 85.39 | Revenue CAGR: 5.70% | SUE: 2.41 | # QB: 3
EPS current Quarter (2027-03-31): EPS=2.28 | Chg30d=-1.00% | Revisions=+25% | Analysts=6
EPS current Year (2026-12-31): EPS=8.96 | Chg30d=-0.02% | Revisions=+25% | GrowthEPS=+22.9% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=9.98 | Chg30d=+0.01% | Revisions=+17% | GrowthEPS=+11.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +38% (up=4, down=1)